Cara Therapeutics, Inc. (CARA)
15.96
-0.69 (-4.14%)
Inactive · Last trade price on Apr 15, 2025

Cara Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
242840577651754
Upgrade
Market Cap Growth
-30.89%-30.89%-92.99%-11.37%-13.64%0.26%
Upgrade
Enterprise Value
3130-35400462626
Upgrade
Last Close Price
15.9618.3626.75386.64438.48544.68
Upgrade
PE Ratio
-----89.65
Upgrade
PS Ratio
3.403.921.9313.7828.285.58
Upgrade
PB Ratio
-5.30-6.090.713.642.863.03
Upgrade
P/TBV Ratio
--0.713.642.863.03
Upgrade
EV/Sales Ratio
4.334.20-9.5520.054.64
Upgrade
EV/EBITDA Ratio
-----111.96
Upgrade
EV/EBIT Ratio
-----116.31
Upgrade
Debt / Equity Ratio
-9.68-9.680.760.010.020.02
Upgrade
Debt / EBITDA Ratio
-----0.79
Upgrade
Asset Turnover
0.080.080.140.200.090.54
Upgrade
Inventory Turnover
19.5619.5643.6439.46--
Upgrade
Quick Ratio
10.6710.674.096.399.559.90
Upgrade
Current Ratio
11.0311.034.547.209.8410.55
Upgrade
Return on Equity (ROE)
-270.01%-270.01%-109.80%-44.25%-37.12%3.86%
Upgrade
Return on Assets (ROA)
-41.09%-41.09%-49.30%-25.49%-21.49%1.33%
Upgrade
Return on Capital (ROIC)
-49.77%-49.77%-58.20%-27.92%-22.94%1.51%
Upgrade
Return on Capital Employed (ROCE)
-----2.10%
Upgrade
Earnings Yield
-291.26%-253.31%-292.78%-14.81%-13.58%1.11%
Upgrade
FCF Yield
-254.66%-221.48%-233.34%-13.65%-9.23%-0.77%
Upgrade
Buyback Yield / Dilution
-1.11%-1.11%-0.92%-5.79%-5.85%-12.29%
Upgrade
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q